Cited by 640Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement DisordersNuclear Receptors and Signaling

The DOI matches its Crossref record; 238 of the 240 references it cites were found in a registry or an index.

Epidemiology of parkinson’s disease

Open access

Tanner, Caroline M., Goldman, Samuel M.·1996·Neurologic Clinics

DOI 10.1016/s0733-8619(05)70259-0PMC PMC7173037

Open this paper in CoChat — free account

Abstract

The epidemiologic studies reviewed here have provided insights into the etiology of PD. Evidence increasingly suggests that, like many other chronic age-related diseases, PD is a multifactorial disorder, with both genes and environment contributing to risk. As the elderly population of the world grows, incidence and prevalence of PD will continue to increase, underscoring the importance of further delineating risk factors. The introduction of levodopa and other pharmacologic therapies over the last 2 decades has postponed disease morbidity and mortality, but morbidity and mortality still are increased markedly relative to unaffected individuals. The development of therapies that may slow disease progression makes early identification and treatment of PD particularly important. Investigations of early markers of PD, or markers of disease susceptibility, are critical areas for future research. These efforts all will be aided by careful collaboration between epidemiologists and laboratory scientists.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0733-8619(05)70259-0

Cites

238 of 238 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
An Essay on the Shaking Palsy
Parkinson, J. (2002) · Journal of Neuropsychiatry · doi:10.1176/jnp.14.2.223 · Cited by 2,856
Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. A., & SEITELBERGER, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,650
Case-Control Studies: Design, Conduct, Analysis.
Youkeles, L., & Schlesselman, J. J. (1983) · Journal of the American Statistical Association · doi:10.2307/2288156 · Cited by 2,358
Vitamin E Consumption and the Risk of Coronary Heart Disease in Men
Rimm, E. B., Stampfer, M. J., Ascherio, A., Giovannucci, E. L., Colditz, G. A., & Willett, W. C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305203282004 · Cited by 2,345
A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
Oxygen radicals and human disease
CROSS, C. E., HALLIWELL, B., BORISH, E. T., PRYOR, W. A., AMES, B. N., SAUL, R. L., McCORD, J. M., & HARMAN, D. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-4-526 · Cited by 1,856
Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects
Nehlig, A., Daval, J., & Debry, G. (1992) · Brain Research Reviews · doi:10.1016/0165-0173(92)90012-b · Cited by 1,463

Show all 240 references

Research works printed but not linked: 13

Breteler, 1995, Risk factors for Parkinson's disease: A population-based case-control study, Neurology, 45, A214
Campanella, 1990, Etiology of Parkinson's disease: Results of two case-control studies, Mov Disord, 5, 31
Davanipour, 1990, Residential histories in Parkinson's disease patients, Ann Neurol, 28, 295
Goetz, 1990, Motor vehicle accident and Parkinson's disease disability, Mov Disord, 5, 16
Kurth, 1995, Lack of association of CYP2D6 and MAO-B alleles with Parkinson's disease in a Kansas cohort, Neurology, 45, A429
Mjones, 1949, Paralysis agitans: A clinical and genetic study, Acta Psychiatry and Neurology, 54, 1
Rocca, 1990, Prevalence of Parkinson's disease and other parkinsonisms: A door-to-door survey in two Sicilian communities, Neurology, 40, 422
Tanner, 1989, Dietary antioxidant vitamins and the risk of developing Parkinson's disease, Neurology, 39, 181
Tanner, 1988, Vitamin use and Parkinson's disease, Ann Neurol, 233, 182
Treves, 1990, Case-control study, with use of temporal approach, for evaluation of risk factors for Parkinson's disease, Mov Disord, 5, 11
Uitti, 1991, Parkinsonism survival in the Levodopa era, Neurology, 41, 190
Vierregge, 1991, Parkinson's disease in twins, Neurology, 41, 255
Zimmerman, 1991, Parkinson's disease in monozygotic twins: A followup, Neurology, 41, 255

Sorted by citations

Parkinson's Disease
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K., Holloway, R. G., Kieburtz, K. D., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A. D., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,479
Self-citation
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Clinical Neurology and Epidemiology of the Major Neurodegenerative DiseasesPreprint
Erkkinen, M. G., Kim, M., & Geschwind, M. D. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033118 · Cited by 1,231
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Parkinson Disease in Twins
Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R. P., & Langston, J. W. (1999) · JAMA · doi:10.1001/jama.281.4.341 · Cited by 876
Self-citation
Polyphenols and Human Health: Prevention of Disease and Mechanisms of Action
Vauzour, D., Rodriguez‐Mateos, A., Corona, G., Oruña-Concha, M. J., & Spencer, J. P. E. (2010) · Nutrients · doi:10.3390/nu2111106 · Cited by 885
Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier
Gilgun‐Sherki, Y., Melamed, E., & Offen, D. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00019-3 · Cited by 850
Association of coffee and caffeine intake with the risk of Parkinson disease
Ross, G. W. (2000) · JAMA · doi:10.1001/jama.283.20.2674 · Cited by 778
Neurodegenerative Diseases and Prions
Prusiner, S. B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105173442006 · Cited by 783
Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases
Chin-Chan, M., Navarro-Yepes, J., & Quintanilla‐Vega, B. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00124 · Cited by 746
“In addition to the aging, which is the main risk factor for PD (Tanner and Goldman, 1996), epidemiological evidence suggests that the exposure to environmental toxicants, mainly pesticides, metals and solvents could increase the risk of developing PD, and factors such as tobacco consumption can…”
Background
Are men at greater risk for Parkinson's disease than women?
Wooten, G. F. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.020982 · Cited by 697
Systematic review of incidence studies of Parkinson's disease
Twelves, D., Perkins, K. S. M., & Counsell, C. E. (2002) · Movement Disorders · doi:10.1002/mds.10305 · Cited by 619
Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis
Kouli, A., Torsney, K., & Kuan, W. (2018) · Codon Publications eBooks · doi:10.15586/codonpublications.parkinsonsdisease.2018.ch1 · Cited by 634
The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders
Knezevic, E., Nenic, K., Milanovic, V., & Knezevic, N. N. (2023) · Cells · doi:10.3390/cells12232726 · Cited by 564
“Stress and aging are prerequisites for neurodegenerative disease [66].”
Background
Mitochondrial Polymorphisms Significantly Reduce the Risk of Parkinson Disease
van der Walt, J. M., Nicodemus, K. K., Martin, E. R., Scott, W. K., NANCE, M. A., Watts, R. L., Hubble, J. P., Haines, J. L., Koller, W. C., Lyons, K. E., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/373937 · Cited by 537
Environmental Toxins and Parkinson's Disease
Goldman, S. M. (2013) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135937 · Cited by 537
Self-citation
Parkin-deficient mice are not a robust model of parkinsonism
Perez, F. A., & Palmiter, R. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409598102 · Cited by 477
Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions
Xu, D.-C., Yong, C., Xu, Y., Chen-Yu, S., & Peng, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01353-3 · Cited by 528
Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates
Collier, T. J., Kanaan, N. M., & Kordower, J. H. (2011) · Nature reviews. Neuroscience · doi:10.1038/nrn3039 · Cited by 469
Environmental risk factors and Parkinson's disease: a metaanalysis.
Priyadarshi, A., Khuder, S., Schaub, E., & Priyadarshi, S. (2001) · Environmental Research · doi:10.1006/enrs.2001.4264 · Cited by 481
The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson’s disease
Pang, S. Y.-Y., Ho, P. W., Liu, H., Leung, C.-T., Li, L., Chang, E. E. S., Ramsden, D. B., & Ho, S. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0165-9 · Cited by 457
Functional Decline in Parkinson Disease
Jankovic, J. J., & Kapadia, A. S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.10.1611 · Cited by 430
Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss
Brooks, A. I., Chadwick, C. A., Gelbard, H. A., Cory‐Slechta, D. A., & Federoff, H. J. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01192-5 · Cited by 425
Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine
Hagan, S., Martin, E., & Enríquez‐de‐Salamanca, A. (2016) · The EPMA Journal · doi:10.1186/s13167-016-0065-3 · Cited by 401
Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai
Zhang, Z., Román, G. C., Hong, Z., Wu, C.-B., Qu, Q.-M., Huang, J.-B., Zhou, B., Geng, Z.-P., Wu, J.-X., Wen, H.-B., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17909-4 · Cited by 398
Microglia Mediated Neuroinflammation in Parkinson’s Disease
Işık, S., Yeman-Kıyak, B., Akbayır, R., Şeyhali-Abutayeh, R., & Arpaci, T. (2023) · Cells · doi:10.3390/cells12071012 · Cited by 419
“5 to 1% in adults aged 60–69 and 1–3% in those over 80 years [1,2].”
Background
Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease
Marogianni, C., Sokratous, M., Dardiotis, E., Hadjigeorgiou, G. M., Bogdanos, D. P., & Xiromerisiou, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228421 · Cited by 384
“The increased incidence of the disease is related to the aging of the population [2].”
Background
Epidemiology of Parkinson Disease
Lee, A., & Gilbert, R. (2016) · Neurologic Clinics · doi:10.1016/j.ncl.2016.06.012 · Cited by 405
Parkinson’s disease risk from ambient exposure to pesticides
Wang, A., Costello, S., Cockburn, M., Zhang, X.-B., Bronstein, J., & Ritz, B. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9574-5 · Cited by 352
Oxidative damage to macromolecules in human Parkinson disease and the rotenone model
Sanders, L. H., & Greenamyre, J. T. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.01.003 · Cited by 360
Mortality in Parkinson's disease: A systematic review and meta‐analysis
Macleod, A. D., Taylor, K. S. M., & Counsell, C. E. (2014) · Movement Disorders · doi:10.1002/mds.25898 · Cited by 328
Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures
Testa, C. M., Sherer, T., & Greenamyre, J. T. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.11.007 · Cited by 296
Iron Deposition Leads to Neuronal α-Synuclein Pathology by Inducing Autophagy Dysfunction
Wan, W., Jin, L., Wang, Z., Wang, L., Fei, G., Ye, F., Pan, X., Wang, C., & Zhong, C. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00001 · Cited by 299
Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective.
Brocks, D. R. (1999) · PubMed · Cited by 291
Complete Genomic Screen in Parkinson Disease
Scott, W. K., Nance, M., Watts, R. L., Hubble, J. P., Koller, W. C., Lyons, K., Pahwa, R., Stern, M. B., Colcher, A., Hiner, B. C., et al. (2001) · JAMA · doi:10.1001/jama.286.18.2239 · Cited by 280
Aging and Parkinson's disease: Different sides of the same coin?
Collier, T. J., Kanaan, N. M., & Kordower, J. H. (2017) · Movement Disorders · doi:10.1002/mds.27037 · Cited by 291
Neurodegeneration and neuroprotection in Parkinson disease
Fahn, S., & Sulzer, D. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.1.139 · Cited by 275
The heterogeneity of idiopathic Parkinson's disease
Foltynie, T., Brayne, C., & Barker, R. A. (2002) · Journal of Neurology · doi:10.1007/pl00007856 · Cited by 254
Etiology of Parkinson’s disease
Schapira, A. H. V. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s10 · Cited by 251
The Marmoset as a Model of Aging and Age-Related Diseases
Tardif, S. D., Mansfield, K. G., Ratnam, R., Ross, C. N., & Ziegler, T. E. (2011) · ILAR Journal · doi:10.1093/ilar.52.1.54 · Cited by 249
The contribution of alpha synuclein to neuronal survival and function – Implications for Parkinson's disease
Benskey, M. J., Perez, R. G., & Manfredsson, F. P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13570 · Cited by 257
“This is in line with epidemiological studies that identify age as the primary risk factor for developing PD (Bennett et al. 1996; Tanner and Goldman 1996).”
Result
Rationale for and use of NMDA receptor antagonists in Parkinson's disease
Hallett, P. J., & Standaert, D. G. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.04.001 · Cited by 238
The diagnosis of manganese-induced parkinsonism
Cersosimo, M. G., & Koller, W. C. (2005) · NeuroToxicology · doi:10.1016/j.neuro.2005.10.006 · Cited by 234
“However, the exact meaning of these epidemiological associations remains unclear, and so far age represents the strongest factor clearly associated with a greater risk of developing PD (Marras and Tanner, 2004).”
Background
Deep learning for freezing of gait detection in Parkinson’s disease patients in their homes using a waist-worn inertial measurement unit
Camps, J., Samà, A., Martín, M., Rodríguez-Martín, D., Pérez-López, C., Moreno Arostegui, J. M., Cabestany, J., Català, A., Alcaine, S., Mestre, B., et al. (2018) · Knowledge-Based Systems · doi:10.1016/j.knosys.2017.10.017 · Cited by 224
Multiple risk factors for Parkinson's disease
Gorell, J. M., Peterson, E. L., Rybicki, B. A., & Johnson, C. C. (2003) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2003.09.014 · Cited by 234
“We and many others [14,15] have shown that environmental and occupational factors are associated with PD.”
Background
Beneficial effects of dietary omega‐3 polyunsaturated fatty acid on toxin‐induced neuronal degeneration in an animal model of Parkinson's disease
Bousquet, M., Saint‐Pierre, M., Julien, C., Salem, N., Cicchetti, F., & Calon, F. (2007) · The FASEB Journal · doi:10.1096/fj.07-9677com · Cited by 232
Astrocytes and Therapeutics for Parkinson's Disease
Rappold, P. M., & Tieu, K. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.07.001 · Cited by 234
Smoking and Parkinson’s disease
Gorell, J. M., Rybicki, B. A., Johnson, C. C., & Peterson, E. L. (1999) · Neurology · doi:10.1212/wnl.52.1.115 · Cited by 224
Gender differences in Parkinson’s disease: A clinical perspective
Georgiev, D., Hamberg, K., Hariz, M., Forsgren, L., & Hariz, G.-M. (2017) · Acta Neurologica Scandinavica · doi:10.1111/ane.12796 · Cited by 220
microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches
Leggio, L., Vivarelli, S., L’Episcopo, F., Tirolo, C., Caniglia, S., Testa, N., Marchetti, B., & Iraci, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122698 · Cited by 218
Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease
Richardson, J. R., Caudle, W. M., Wang, M., Dean, E. D., Pennell, K. D., & Miller, G. W. (2006) · The FASEB Journal · doi:10.1096/fj.06-5864fje · Cited by 215
α-Synuclein: Normal Function and Role in Neurodegenerative Diseases
Norris, E. H., Giasson, B. I., & Lee, V. M. ‐. (2004) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(04)60002-0 · Cited by 208
Mitochondria in Neurodegeneration
Lezi, E., & Swerdlow, R. H. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2869-1_12 · Cited by 213
Dieldrin-Induced Neurotoxicity: Relevance to Parkinson's Disease Pathogenesis
Kanthasamy, A. G., Kitazawa, M., Kanthasamy, A., & Anantharam, V. (2004) · NeuroToxicology · doi:10.1016/j.neuro.2004.07.010 · Cited by 201
Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases
Perry, E. K., Martin-Ruiz, C. M., Lee, M., Griffiths, M., Johnson, M., Piggott, M. A., Haroutunian, V. H., Buxbaum, J. D., Nãsland, J., Davis, K. L., et al. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00064-9 · Cited by 201
Progress in Parkinson's disease—Where do we stand?
Toulouse, A., & Sullivan, A. M. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.05.003 · Cited by 197
SIRT1 ameliorates oxidative stress induced neural cell death and is down-regulated in Parkinson’s disease
Singh, P., Hanson, P. S., & Morris, C. M. (2017) · BMC Neuroscience · doi:10.1186/s12868-017-0364-1 · Cited by 193
Association of Single-Nucleotide Polymorphisms of the Tau Gene With Late-Onset Parkinson Disease
Martin, E. R. (2001) · JAMA · doi:10.1001/jama.286.18.2245 · Cited by 191
Syntax, action verbs, action semantics, and object semantics in Parkinson's disease: Dissociability, progression, and executive influences
Bocanegra, Y., García, A. M., Pineda, D. A., Buriticá, O., Villegas, A., Lopera, F. J., Gómez, D., Gómez-Arias, C., Cardona, J. F., Trujillo, N., et al. (2015) · Cortex · doi:10.1016/j.cortex.2015.05.022 · Cited by 198
“Of particular importance to this line of research is the study of linguistic and semantic skills in Parkinson̓s disease (PD), the second most prevalent neurodegenerative disorder worldwide (Tanner & Goldman, 1996).”
Background
Neuroprotective Herbs and Foods from Different Traditional Medicines and Diets
Iriti, M., Vitalini, S., Fico, G., & Faoro, F. (2010) · Molecules · doi:10.3390/molecules15053517 · Cited by 191
Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study
Nilsson, F. M., Kessing, L. V., & Bolwig, T. G. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.00372.x · Cited by 180
High prevalence of parkinsonian disorders associated to manganese exposure in the vicinities of ferroalloy industries
Lucchini, R. G., Albini, E., Benedetti, L., Borghesi, S., Coccaglio, R., Malara, E. C., Parrinello, G., Garattini, S., Resola, S., & Alessio, L. (2007) · American Journal of Industrial Medicine · doi:10.1002/ajim.20494 · Cited by 179
The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor
Neal, M. P., Boyle, A. M., Budge, K. M., Safadi, F. F., & Richardson, J. R. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1100-1 · Cited by 181
The Pathogenesis of Parkinson's Disease: A Complex Interplay Between Astrocytes, Microglia, and T Lymphocytes?
Copas, A. N. M., McComish, S. F., Fletcher, J. M., & Caldwell, M. A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.666737 · Cited by 186
Effects of speech therapy and pharmacologic and surgical treatments on voice and speech in parkinson's disease
Schulz, G. M., & Grant, M. K. (2000) · Journal of Communication Disorders · doi:10.1016/s0021-9924(99)00025-8 · Cited by 174
Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: Diminished compensatory mechanisms as a prelude to parkinsonism
Collier, T. J., Lipton, J., Daley, B. F., Palfi, S., Chu, Y., Sortwell, C., Bakay, R. A. E., Sladek, J. R., & Kordower, J. H. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.11.013 · Cited by 162
“Aging is a well-established risk factor for PD (Mayeux et al., 1995; Tanner and Goldman, 1996; Totaro et al., 2005).”
Background
Genetic and environmental risk factors for Parkinson's disease in a Chinese population
Chan, D., Woo, J., Ho, S. C., Pang, C. P., Law, L. K., Ng, P. W., Hung, W. T., Kwok, T. C. Y., Hui, E., Orr, K., et al. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.65.5.781 · Cited by 169
Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy‐like tauopathy
Caparros-Lefebvre, D., Sergeant, N., Lees, A. J., Camuzat, A., Daniel, S. E., Lannuzel, A., Brice, A., TOLOSA, E. S., Delacourte, A., & Duyckaerts, C. J. (2002) · Brain · doi:10.1093/brain/awf086 · Cited by 169
“Such a distribution contrasts with the one encountered in Europe and North America, where classical Parkinson's disease is by far the commonest diagnosis among patients with Parkinson's disease (de Rijk et al., 1997; Golbe et al., 1988; Tanner and Goldman, 1996).”
Result
Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes
Weaver, F. M., Follett, K. A., Hur, K., Ippolito, D., & Stern, M. (2005) · Journal of neurosurgery · doi:10.3171/jns.2005.103.6.0956 · Cited by 168
The mitochondrial complex i inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism
Lannuzel, A., Michel, P. P., Höglinger, G. U., Champy, P., Jousset, A. B., Medja, F., Lombès, A., Darios, F. D., Gleye, C., Laurens, A., et al. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00441-x · Cited by 168
Drug Dosage in the Elderly
Turnheim, K. (1998) · Drugs & Aging · doi:10.2165/00002512-199813050-00003 · Cited by 166
“[94] Other neuronal receptor systems that may be altered in old age of experimental animals include the γ-aminobutyricacid (GABA)A receptors and the N-methyl-Daspartate (NMDA) receptors.”
Background
Update on Parkinson Disease
Siderowf, A. D., & Stern, M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-8-200304150-00013 · Cited by 164
Verbal Fluency Task Affects Gait in Parkinson's Disease with Motor Freezing
Camicioli, R. M., Oken, B., Sexton, G. J., Kaye, J. A., & Nutt, J. G. (1998) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879901100403 · Cited by 155
Cardiac abnormalities in Parkinson’s disease and Parkinsonism
Scorza, F. A., FIORINI, A. C., Scorza, C. A., & Finsterer, J. (2018) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2018.04.031 · Cited by 156
Levodopa-induced dyskinesia: clinical features, incidence, and risk factors
Tran, T. N., Vo, T. N. N., Frei, K. P., & Truong, D. D. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1900-6 · Cited by 151
A novel transactivation domain in parkin
Morett, E., & Peer Bork, B. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(99)01381-x · Cited by 151
Speech Disorders in Parkinson’s Disease: Pathophysiology, Medical Management and Surgical Approaches
Dashtipour, K., Tafreshi, A., Lee, J. K., & Crawley, B. K. (2018) · Neurodegenerative Disease Management · doi:10.2217/nmt-2018-0021 · Cited by 150
Risk-factors for Parkinson's disease: case-control study in the province of Cáceres, Spain
Morano, A. E., Jiménez‐Jiménez, F. J., Pérez-Molina, J. A., & Antolín, M. A. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1994.tb01655.x · Cited by 150
Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families
Pankratz, N. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg270 · Cited by 151
Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult
Henderson, M. X., Sedor, S. F., McGeary, I., Cornblath, E. J., Peng, C., Riddle, D. M., Li, H. L., Zhang, B., Brown, H. J., Olufemi, M. F., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.12.004 · Cited by 150
Major depressive disorder in Parkinson's disease: a register‐based study
Nilsson, F. M., Kessing, L. V., Sørensen, T. M., Andersen, P. K., & Bolwig, T. G. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.02229.x · Cited by 145
Reliability of Impairment and Physical Performance Measures for Persons With Parkinson's Disease
Schenkman, M. L., Cutson, T. M., Kuchibhatla, M. N., Chandler, J., & Pieper, C. F. (1997) · Physical Therapy · doi:10.1093/ptj/77.1.19 · Cited by 147
Circadian rhythm of periodic limb movements and sensory symptoms of restless legs syndrome
Trenkwalder, C., Hening, W. A., Walters, A. S., Campbell, S. S., Rahman, K., & Chokroverty, S. (1999) · Movement Disorders · doi:10.1002/1531-8257(199901)14:1 · Cited by 226
Anti-aging herbal medicine—How and why can they be used in aging-associated neurodegenerative diseases?
Ho, J. Y. S., So, K., & Chang, R. C. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2009.10.001 · Cited by 140
Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and α‐synuclein inclusions
Gibrat, C., Saint‐Pierre, M., Bousquet, M., Lévesque, D., Rouillard, C., & Cicchetti, F. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06072.x · Cited by 136
“Parkinson’s disease (PD) is recognized as the second most common neurodegenerative disorder after Alzheimer’s disease and affects 1% of the population worldwide after the age of 65 years (Tanner and Goldman 1996).”
Background
Epidemiology of Parkinsonʼs disease and akinetic syndromes
Tanner, C. M., & Aston, D. A. (2000) · Current Opinion in Neurology · doi:10.1097/00019052-200008000-00010 · Cited by 133
Self-citation
Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability
Zucca, F. A., Bellei, C., Giannelli, S. G., Terreni, M., Gallorini, M., Rizzio, E., Pezzoli, G., Albertini, A., & Zecca, L. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0453-2 · Cited by 132
The best medicine? The influence of physical activity and inactivity on Parkinson's disease
LaHue, S. C., Comella, C. L., & Tanner, C. M. (2016) · Movement Disorders · doi:10.1002/mds.26728 · Cited by 138
Self-citation
Mean-field modeling of the basal ganglia-thalamocortical system. II
van Albada, S. J., Gray, R. T., Drysdale, P. M., & Robinson, P. A. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2008.12.013 · Cited by 133
Epidemiology of Parkinson's disease
Kasten, M., Chade, A., & Tanner, C. M. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83006-5 · Cited by 134
Self-citation
Psychiatric Manifestation in Patients with Parkinson's Disease
Han, J. W., Ahn, Y. D., Kim, W.-S., Shin, C. M., Jeong, S. J., Song, Y. S., Bae, Y. J., & Kim, J.-M. (2018) · Journal of Korean Medical Science · doi:10.3346/jkms.2018.33.e300 · Cited by 127
The health burdens of Parkinson's disease
Chrischilles, E. A., Rubenstein, L. M., Voelker, M. D., Wallace, R. B., & Rodnitzky, R. L. (1998) · Movement Disorders · doi:10.1002/mds.870130306 · Cited by 127
Occupational Metal Exposures and the Risk of Parkinson’s Disease
Raterman, K. (2011) · Cited by 124
Mitochondrial Ca2+ Signaling in Health, Disease and Therapy
Modesti, L., Danese, A., Vitto, V. A. M., Ramaccini, D., Aguiari, G., Gafà, R., Lanza, G., Giorgi, C., & Pinton, P. (2021) · Cells · doi:10.3390/cells10061317 · Cited by 123
Aging of the nigrostriatal system in the squirrel monkey
McCormack, A. L., Monte, D. A. D., Delfani, K., Irwin, I., DeLanney, L. E., Langston, J. W., & Janson, A. M. (2004) · The Journal of Comparative Neurology · doi:10.1002/cne.20036 · Cited by 120
Polychlorinated Biphenyl–Induced Reduction of Dopamine Transporter Expression as a Precursor to Parkinson's Disease–Associated Dopamine Toxicity
Caudle, W. M., Richardson, J. R., Delea, K. C., Guillot, T. S., Wang, M., Pennell, K. D., & Miller, G. W. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfl018 · Cited by 120
Etiology and Pathogenesis of Parkinson Disease
Schapira, A. H. V. (2009) · Neurologic Clinics · doi:10.1016/j.ncl.2009.04.004 · Cited by 120
Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1)
Barrero, F. J., Ampuero, I., Morales, B., Vives, F., Luna, J. D. D., Hoenicka, J., & de Yébenes, J. G. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500301 · Cited by 117
Alpha-Synuclein PET Tracer Development—An Overview about Current Efforts
Korat, Š., Bidesi, N., Bonanno, F., Nanni, A. D., Hoàng, A. N. N., Herfert, K., Maurer, A., Battisti, U. M., Bowden, G. D., Thonon, D., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14090847 · Cited by 120

Authors: Tanner, C. M., & Goldman, S. M.
Affiliations: Parkinson's Institute and Clinical Center (US)
ORCID: Tanner, Caroline M.
Goldman, Samuel M.
Venue: Neurologic Clinics
Publisher: Elsevier BV
Published: 1996-05
Volume: 14
Issue: 2
Pages: 317-335
ISSN: 0733-8619 (ISSN-L)
DOI: 10.1016/s0733-8619(05)70259-0
PMC: PMC7173037
OpenAlex: W2084553926
Semantic Scholar: 722f96a983f226977773068a6a70c00979c0cbd5
Cited by: 640
References: 240
Citations by year: 2026: 9 · 2025: 10 · 2024: 17 · 2023: 29 · 2022: 23 · 2021: 26 · 2020: 14 · 2019: 24 · 2018: 35 · 2017: 36 · 2016: 28 · 2015: 26 · 2014: 32 · 2013: 28 · 2012: 19
FWCI: 11.14
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Neurologic Clinics (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (R01CA094089)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: Parkinson's disease, etiology, complex diseases, genetic risk factors, environmental risk factors, incidence, prevalence, levodopa, early markers, disease susceptibility, disease progression
MeSH terms: Aged, Consanguinity, Diet, Environmental Exposure, Female, Humans, Male, Middle Aged, Parkinson Disease, Risk Factors, Smoking, Global Health, Hazardous Substances, Incidence, Prevalence, Age Distribution, Sex Distribution, Patient Selection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidemiology of parkinson’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks